Use of breath-actuated inhalers in patients with asthma and COPD-an advance in inhalational therapy: A systematic review

Expert Review of Respiratory Medicine

Volumn 8, Issue 1, 2014, Pages 89-99

  Salvi, Sundeep ^a   Gogtay, Jaideep ^b   Aggarwal, Bhumika ^b  

^a Marigold Complex   (India)

^b CIPLA LTD   (India)

Author keywords

asthma; breath activated metered dose inhaler; breath actuated inhaler; COPD

Indexed keywords

ASTHMA; BREATH ACTUATED INHALER; CHILD CARE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; ECONOMIC EVALUATION; ELDERLY CARE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INHALER; LUNG FUNCTION; PATIENT PREFERENCE; REVIEW; SYSTEMATIC REVIEW;

ADMINISTRATION, INHALATION; ANTI-ASTHMATIC AGENTS; ASTHMA; COST-BENEFIT ANALYSIS; EQUIPMENT DESIGN; HUMANS; METERED DOSE INHALERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATION; RESPIRATORY THERAPY; TREATMENT OUTCOME;

EID: 84893142975     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2014.854168     Document Type: Review

References (59)

1. Hess DH. Aerosol delivery devices in the treatment of asthma. Respir. Care. 53, 699-723 (2008).
2. Pedersen S, Dubus JC, Crompton G, on behalf of the ADMIT Working Group the ADMIT series-Issues in Inhalation Therapy. Inhaler selection in children with asthma. Prim. Care Respir. J. 19, 209-216 (2010).
3. Coady TJ, Davies HJ, Barnes P. Evaluation of a breath actuated pressurized aerosol. Clin. Allergy 6, 1-6 (1976).
4. Fergusson RJ, Lenney J, McHardy GJ, Crompton GK. The use of a new breath-Actuated inhaler by patients with severe airflow obstruction. Eur. Respir. J. 4, 172-174 (1991).
5. Tashkin DP. New devices for asthma. J. Allergy Clin. Immunol. 101, S409-416 (1998).
6. Baum EA, Bryant AM. The development and laboratory testing of a novel breath-Actuated pressurised inhaler. J. Internat. Soc. Aerosols. 2, 219 (1988).
7. Ganderton D. General factors influencing drug delivery to the lung. Respir. Med. 91(Suppl. A) 13-16 (1997).
8. Newman SP. Principles of metered-dose inhaler design. Respir. Care 50, 1177-1190 (2005).
9. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation and performance. Respir. Med. 96, 293-304 (2002).
10. Bronsky EA, Debelic M, Jean-Claude, Hahn M. Ease-of-Use Study of Pirbuterol Acetate in the Autohaler Actuator in Three Countries: The United States, Germany, and France. J. Asthma 30, 439-443 (1993).
11. Larsen JS, Hahn M, Kochevar JW. et al.: Administration errors with a conventional metered dose inhaler versus a novel breath actuated device. Ann. Allergy 71, 103-106 (1993).
12. Kelloway JS, Kochevar JW, Sveum RJ, Hahn MA. Evaluation of the Autohaler actuator: The effect of written patient instructions on correct use. J. Asthma 30, 373-379 (1993).
13. Price DB, Pearce L, Powell SR, Shirley J, Sayers MK. Handling and acceptability of the Easi-Breathe device compared with a conventional metered dose inhaler by patients and practice nurses. Int. J. Clin. Pract. 53, 31-36 (1999).
14. Giraud V, Allaert FA, Magnan A. A prospective observational study of patient training in use of the autohaler inhaler device: The Sirocco study. Eur. Rev. Med. Pharmacol. Sci. 15, 563-570 (2011).
15. Newman SP, Weisz AW, Talaee N, Clarke SW. Improvement of 'drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 46, 712-716 (1991).
16. Marshik PL, Larsen JS, Leach CL. et al.: A novel breath actuated device (Autohaler) consistently actuates during the early phase of inspiration. J. Aerosol. Med. 8, 187-195 (1995).
17. Terzano C, Mannino F. Probability of particle and salbutamol deposition in the respiratory tract: Comparison between MDI and Autohaler. Monaldi Arch. Chest Dis. 51, 236-242 (1996).
18. Lipworth BJ, Clark DJ. Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices. Pulm. Pharmacol. Ther. 10, 211-214 (1997).
19. Kamin WE, Genz T, Roeder S. et al.: Mass output and particle size distribution of glucocorticosteroids emitted from different inhalation devices depending on various inspiratory parameters. J. Aerosol. Med. 15, 65-73 (2002).
20. Aswania O, Ritson S, Iqbal SM, Bhatt J, Rigby AS, Everard ML. Intra-subject variability in lung dose in healthy volunteers using five conventional portable inhalers. J. Aerosol. Med. 17, 231-238 (2004).
21. Crompton G, Duncan J. Clinical assessment of a new breath actuated inhaler. Practitioner 233, 268-269 (1989).
22. Chapman KR, Love L, Brubaker H. A comparison of breath-Actuated and conventional metered-dose inhaler inhalation techniques in elderly subjects. Chest 104, 1332-1337 (1993).
23. Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: Assessment of use and patient preference of seven inhalation devices. Respir. Med. 94, 496-500 (2000).
24. vanSchayck CP, Bijl-Hofland ID, Folgering H. et al.: Influence of two different inhalation devices on therapy compliance in asthmatic patients. Scand. J. Prim. Health Care 20, 126-128 (2002).
25. Steier J, Trammer T, Cloes RM, Zetterstrom O, van den Elshout FJ, Laitinen LA. Optical feedback training of inhalation with autohaler and turbuhaler in COPD patients. Lung 181, 183-192 (2003).
26. Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N. Assessment of Handling of Inhaler Devices in Real Life: An Observational Study in 3811 Patients in Primary Care. J. Aerosol. Med. 16, 249-254 (2003).
27. Molimard M, Martinat Y, Rogeaux Y, Moyse D, Pello JY, Giraud V. Improvement of asthma control with beclomethasoneextrafine aerosol compared to fluticasone and budesonide. Respir. Med. 99, 770-778 (2005).
28. Giraud V, Allaert FA. Improved asthma control with breath-Actuated pressurized Metered Dose Inhaler (pMDI): The SYSTER survey. Eur. Rev. Med. Pharmacol. Sci. 13, 323-330 (2009).
29. Jarvis S, Ind PW, Shiner RJ. Inhaled therapy in elderly COPD patients; time for re-evaluatioñ Age Ageing 36, 213-218 (2007).
30. Rau JL. Practical Problems with Aerosol Therapy in COPD. Respir. Care 51, 158-172 (2006).
31. Crompton GK. Breath activated aerosol. BMJ 2, 652-653 (1971).
32. Pedersen S, Frost L, Arnfred T. Errors in inhalation technique and efficiency in inhaler use in asthmatic children. Allergy 41, 118-124 (1986).
33. Pedersen S, Mortensen S. Use of different inhalation devices in children. Lung 168 (Suppl.), 653-657 (1990).
34. Ruggins NR, Milner AD, Swarbrick A. An assessment of a new breath actuated inhaler device in acutely wheezy children. Arch. Dis. Child 68, 477-480 (1993).
35. Arshad H, Luyt D, Goodwin A, Jones A, Hide D, Williams I. Sodium cromoglycate via inhaler and Autohaler. Respir. Med. 87, 299-302 (1993).
36. Devadason SG, Huang T, Walker S, Troedson R, Le Souéf PN. Distribution of technetium-99 m-labelled QVAR delivered using an Autohaler device in children. Eur. Respir. J. 21, 1007-1011 (2003).
37. Petersen R, Agertoft L, Pedersen S. Treatment of exercise-induced asthma with beclomethasonedipropionate in children with asthma. Eur. Respir. J. 24, 932-937 (2004).
38. Donnell D. Inhaled corticosteroid delivery systems: Clinical role of a breath-Actuated device. Eur. Rev. Med. Pharmacol. Sci. 5, 7-16 (2001).
39. Williams DM, Brock TP. Clinical considerations in the use of inhalation delivery devices. J. Pharm. Pract. 14, 277-295 (2001).
40. Allen SC, Prior A. What determines whether an elderly patient can use a metered dose inhaler correctly? Br. J. Dis. Chest 80, 45-49 (1986).
41. Armitage JM, Williams SJ. Inhaler technique in the elderly. Ageing 17, 275-278 (1988).
42. Diggory P, Bailey R, Vallon A. Effectiveness of inhaled bronchodilator delivery systems for elderly patients. Age Aging 20, 379-382 (1991).
43. Arthur V, Pushkin S, Emery P. Inhaler use in patients with arthritic hands. Clin. Trials Meta Anal. 28, 23-28 (1992).
44. Jones V, Fernandez C, Diggory P. A comparison of large volume spacer, breath-Activated and dry powder inhalers in older people. Age Ageing 28, 481-484 (1999).
45. Langley PC. The technology of metered-dose inhalers and treatment costs in asthma: A retrospective study of breath actuation versus traditional press-And-breathe inhalers. Clin. Ther. 21, 236-252 (1999).
46. Anandan C, Nurmatov U, van Schayck OC, Sheikh. Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy 65, 152-167 (2010).
47. Bousquet J, Bousquet PJ, Godard P, Daures JP. "The public health implications of asthma." Bull. World Health Organ. 83(7), 548-554 (2005).
48. Kelloway JS, Wyatt RA. A cost-effectiveness analysis of breath-Actuated metered-dose inhalers. Manag. Care Interface 10, 99-107 (1997).
49. Haycox A, Mitchell G, Niziol C, Featherstone R. Cost effectiveness of asthma treatment with a breath-Actuated pressurised metered dose inhaler (BAI)-A prescribing claims study of 1856 patients using a traditional pressurised metered dose inhaler (MDI) or a breath-Actuated device. J. Med. Econ. 5, 66-77 (2002).
50. Haycox A, Mota RM, Featherstone R. Evaluating the cost effectiveness of asthma inhaler systems: An observational study of patients in General Practice in the UK. J. Med. Econ. 10, 297-308 (2007).
51. Price D, Thomas M, Mitchell G, Niziol C, Featherstone R. Improvement of asthma control with a breath actuated pressurised metred dose inhaler (BAI): A prescribing claims study of 5556 patients using a traditional pressurised metred dose inhaler (MDI) or a breath-Actuated device. Respir. Med. 97, 12-19 (2003).
52. Haycox A, Featherstone R. Cost effectiveness of asthma treatment with a breath-Actuated inhaler: How has the story changed? J. Med. Econ. 11, 525-539 (2008).
53. Laube BL, Janssens HM, de Jongh FH. et al.: European Respiratory Society; International Society for Aerosols in Medicine. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 37, 1308-1331 (2011).
54. Völkl KP, Kroll VM, Wiesemann HG, Schneider B. Clinical efficacy of two beta 2-sympathicomimetics in different inhalers in children with asthma. Comparison of pirbuterol in a breath-Actuated inhaler and salbutamol in a customary metered-dose inhaler. Arzneimittelforschung 41, 533-536 (1991).
55. Waterhouse JC, Simmons JL, Wray H, Howard P. Comparative assessment of a new breath-Actuated inhaler in patients with reversible airways obstruction. Respiration 59, 155-158 (1992).
56. Woodman K, Bremner P, Burgess C, Crane J, Pearce N, Beasley R. A comparative study of the efficacy of beclomethasonedipropionate delivered from a breath activated and conventional metered dose inhaler in asthmatic patients. Curr. Med. Res. Opin.13, 61-69 (1993).
57. Schecker MH, Wilson AF, Mukai DS, Hahn M, Crook D, Novey HS. A device for overcoming discoordination with metered-dose inhalers. J. Allergy Clin. Immunol. 92, 783-789 (1993).
58. Reichel W, Dahl R, Ringdal N. et al.: Extrafine beclomethasone dipropionate breath-Actuated inhaler (400 micrograms/ day) versus budesonide dry powder inhaler (800 micrograms/day) in asthma. Int. J. Clin. Pract. 55, 100-106 (2001).
59. Gross G, Cohen RM, Guy H. Efficacy response of inhaled HFA-Albuterol delivered via the breath-Actuated Autohaler inhalation device is comparable to dose in patients with asthma. J. Asthma 40, 487-495 (2003).